Search results for "Lymphocyte"

showing 10 items of 2280 documents

Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis

2017

Objective: To investigate the role of macrophage migration inhibitory factor (MIF) in the pathogenesis of ankylosing spondylitis (AS). Methods: Patients who met the modified New York criteria for AS were recruited for the study. Healthy volunteers, rheumatoid arthritis patients, and osteoarthritis patients were included as controls. Based on the annual rate of increase in modified Stoke AS Spine Score (mSASSS), AS patients were classified as progressors or nonprogressors. MIF levels in serum and synovial fluid were quantitated by enzyme-linked immunosorbent assay. Predictors of AS progression were evaluated using logistic regression analysis. Immunohistochemical analysis of ileal tissue was…

AnkylosingAdultMaleLogistic ModelMacrophageImmunologyEnzyme-Linked Immunosorbent AssayIntramolecular OxidoreductasePredictive Value of TestMonocyteSeverity of Illness IndexCalcificationCalcification PhysiologicPaneth CellRheumatologySynovial Fluidotorhinolaryngologic diseasesImmunology and AllergySpondylitis AnkylosingPhysiologicSpondylitiMacrophage Migration-Inhibitory FactorTumor Necrosis Factor-alphaOsteoblastB-LymphocyteHistocompatibility Antigens Class IIMiddle AgedSpineAntigens Differentiation B-LymphocyteSettore MED/16 - ReumatologiaAntigenDifferentiationDisease ProgressionFemaleCase-Control StudieHuman
researchProduct

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

2015

How dying tumor cells get noticed Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and ov…

AnthracyclineColorectal cancermedicine.medical_treatmentT-LymphocytesBreast Neoplasmsmicrofluidic chipchemotherapyPolymorphism Single NucleotideFormyl peptide receptor 1immune responseMiceImmune systemImmunityCell Line TumorNeoplasmsmedicineLeukocytesAnimalsHumansAnthracyclinesAllelesAnnexin A1ChemotherapyMultidisciplinarybusiness.industryDendritic Cellsmedicine.diseaseReceptors Formyl PeptideImmunity InnateChemotherapy AdjuvantCancer cellImmunologyCancer researchFemalebusinessColorectal NeoplasmsAdjuvantFPR1 microfluidicScience (New York, N.Y.)
researchProduct

In vitro study of alloreactivity and microchimerism after injection of dendritic cells and anti-CD4 monoclonal antibody in a combination of Lewis-Wis…

1998

Anti-CD4 Monoclonal Antibodymedicine.drug_classT-LymphocytesAntigen presentationRats Inbred WFBiologyMonoclonal antibodyLymphocyte ActivationImmune toleranceIsoantibodiesmedicineAnimalsTransplantation HomologousAntigen-presenting cellTransplantationTransplantation ChimeraAntibodies MonoclonalMicrochimerismDendritic cellDendritic CellsIn vitroRatsRats Inbred LewImmunologyCD4 AntigensCancer researchSurgeryTransplantation proceedings
researchProduct

Synthesis of new 2,3-diaryl-1,3-thiazolidin-4-ones as anti-HIV agents

2004

Several 2,3-diaryl-1,3-thiazolidin-4-ones were synthesized and evaluated as anti-HIV agents. The results of the in vitro tests showed that some of them were highly effective inhibitors of HIV-1 replication at 30-50 nM concentrations with minimal cytotoxicity, thereby acting as non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs).

Anti-HIV activity23-diaryl-13-thiazolidin-4-oneAnti-HIV AgentsCell SurvivalT-LymphocytesDrug Evaluation PreclinicalPharmaceutical SciencePharmacologyVirus ReplicationStructure-Activity RelationshipDrug DiscoveryStructure–activity relationshipHumansCytotoxicityCell survivalAnti hiv activityMolecular StructureAnti hivChemistryvirus diseasesSettore CHIM/08 - Chimica FarmaceuticaReverse transcriptaseIn vitroThiazolesViral replicationHIV-2HIV-1NNRTIsReverse Transcriptase Inhibitors
researchProduct

Cellular and humoral immune responses against cancer: implications for cancer vaccines.

1991

The key issue in tumor immunology is to identify antigens as target structures for a cancer-selective immunological attack in the tumor-bearing host, resulting in tumor rejection. There is a growing detailed understanding of structural and regulatory gene alterations giving rise to candidate rejection antigens and peptides in tumor cells. As well as reviewing the development of new adjuvant and recombinant vector systems, new approaches are suggested for the construction of cancer vaccines.

Antibodies Neoplasmmedicine.medical_treatmentImmunologyBiologyMajor histocompatibility complexMiceImmune systemAntigenAntigens NeoplasmGangliosidesNeoplasmsmedicineImmunology and AllergyAnimalsHumansVector (molecular biology)Immunity CellularLymphokinesVaccinesVaccines SyntheticCancerNeoplasms Experimentalmedicine.diseaseCTL*ImmunologyAntibody Formationbiology.proteinBCG VaccineCytokinesTumor necrosis factor alphaAdjuvantT-Lymphocytes CytotoxicCurrent opinion in immunology
researchProduct

K Cell Activity of Normal and Chronic Lymphocytic Leukaemia Lymphocytes: Association with Lymphocytes bearing Receptors for Human C3b

1977

Surface properties of effector cells in antibody-dependent cell mediated cytotoxicity (ADCC) are at present under intensive investigation. Among these cells a lymphocyte population (K cells) has been described with receptors for the Fc portion of IgG (4), receptors for complement (11) and lacking receptors for sheep red blood cells (SRBC) and surface immunoglobulin (13). The purpose of the present study was to investigate more thoroughly the relationship between K cell activity in ADCC and cells bearing receptors for C3b and C3d.

Antibody-dependent cell-mediated cytotoxicityeducation.field_of_studyLymphocytic leukaemiaSurface ImmunoglobulinEffectorChemistryLymphocytePopulationchemical and pharmacologic phenomenak-cellMolecular biologymedicine.anatomical_structuremedicineReceptoreducation
researchProduct

Chemotherapy and immunomodulation: from immunogenic chemotherapies to novel therapeutic strategies.

2013

Anticancer immunityCancer ResearchOrganoplatinum Compoundsmedicine.medical_treatmentBreast NeoplasmsT-Lymphocytes RegulatoryImmunomodulationChemoimmunotherapyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesCyclophosphamideChemotherapyCell Deathbusiness.industryImmunosuppressionInflammasomeGeneral MedicineOxaliplatinOncologyImmunologyMyeloid-derived Suppressor CellFemaleFluorouracilbusinessImmunosuppressive Agentsmedicine.drugFuture oncology (London, England)
researchProduct

Flow cytometric immunophenotyping: principles and pitfalls

1992

Within the last decade flow cytometry (FCM) has become an integral part of basic immunological research. Elaboration of this technology has been intensively stimulated by a rapidly growing sophistication in monoclonal antibody technology and vice versa. At present numerous applications are established that allow an increasingly detailed insight into the immune system, however, automation still must be considered the "cinderella of the arts". Thus, transition of this powerful approach from a basic to a routine clinical procedure is much more difficult than expected. Sufficient usage of flow cytometers still requires some knowledge of physics and its technical applications. Moreover, several …

Anticorps monoclonalbusiness.industrymedia_common.quotation_subjectAntibodies MonoclonalCell SeparationBiologyFlow CytometryAutomationData scienceMonocytesImmunophenotypingFlow (mathematics)Pediatrics Perinatology and Child HealthImmunologyHumansLymphocytesbusinessSophisticationmedia_commonEuropean Journal of Pediatrics
researchProduct

Generation of monoclonal antibodies against human regulatory T cells.

2009

Abstract Natural CD4 + CD25 + Foxp3 + regulatory T cells (Tregs) control the activation of the immune system and therefore have become a major area of research in immunology. The generation of monoclonal antibodies against human Tregs offers the possibility to discover novel Treg-specific or Treg-associated surface markers and to identify targets for a therapeutic modulation of Tregs. Here we present a methodology optimized to efficiently induce and select mAb against human Tregs by repeated immunization of mice with Tregs from a single donor and a differential two-step flow cytometry-based hybridoma screening procedure.

Anticorps monoclonalmedicine.drug_classImmunologyReceptors Antigen T-Cellchemical and pharmacologic phenomenaCell SeparationBiologyMonoclonal antibodyT-Lymphocytes RegulatoryFlow cytometryEpitopesMiceImmune systemAntibody SpecificitymedicineImmunology and AllergyAnimalsHumansIL-2 receptorLeukapheresisImmunization ScheduleHybridomasmedicine.diagnostic_testInterleukin-2 Receptor alpha SubunitFOXP3Antibodies Monoclonalhemic and immune systemsForkhead Transcription FactorsT lymphocyteFlow CytometryImmunizationImmunologyFemaleEpitope MappingJournal of immunological methods
researchProduct

Mechanism in allergic contact dermatitis.

1993

Antigen PresentationCell adhesion moleculeMechanism (biology)ChemistryAntigen presentationDermatologymedicine.diseaseBiochemistryT-Lymphocyte SubsetsLangerhans CellsImmunologyDermatitis Allergic ContactmedicineCytokinesHumansSignal transductionMolecular BiologyHaptenAllergic contact dermatitisCell Adhesion MoleculesLymphocyte subsetsSignal TransductionExperimental dermatology
researchProduct